JP2017519000A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519000A5
JP2017519000A5 JP2016572403A JP2016572403A JP2017519000A5 JP 2017519000 A5 JP2017519000 A5 JP 2017519000A5 JP 2016572403 A JP2016572403 A JP 2016572403A JP 2016572403 A JP2016572403 A JP 2016572403A JP 2017519000 A5 JP2017519000 A5 JP 2017519000A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
ocf
enyl
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016572403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519000A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/035400 external-priority patent/WO2015191900A1/en
Publication of JP2017519000A publication Critical patent/JP2017519000A/ja
Publication of JP2017519000A5 publication Critical patent/JP2017519000A5/ja
Pending legal-status Critical Current

Links

JP2016572403A 2014-06-12 2015-06-11 グルカゴンアンタゴニスト Pending JP2017519000A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462011547P 2014-06-12 2014-06-12
US62/011,547 2014-06-12
US201462073916P 2014-10-31 2014-10-31
US62/073,916 2014-10-31
US201462078926P 2014-11-12 2014-11-12
US62/078,926 2014-11-12
PCT/US2015/035400 WO2015191900A1 (en) 2014-06-12 2015-06-11 Glucagon antagonists

Publications (2)

Publication Number Publication Date
JP2017519000A JP2017519000A (ja) 2017-07-13
JP2017519000A5 true JP2017519000A5 (enExample) 2018-07-19

Family

ID=54834341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572403A Pending JP2017519000A (ja) 2014-06-12 2015-06-11 グルカゴンアンタゴニスト

Country Status (4)

Country Link
US (2) US10076504B2 (enExample)
EP (1) EP3154956A4 (enExample)
JP (1) JP2017519000A (enExample)
WO (1) WO2015191900A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2615481T3 (es) 2008-08-13 2017-06-07 Metabasis Therapeutics, Inc. Antagonistas de glucagón
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN106336387A (zh) * 2015-07-10 2017-01-18 浙江海正药业股份有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
BR112018076703A2 (pt) * 2016-06-27 2019-04-02 President And Fellows Of Harvard College compostos úteis para tratar distúrbios metabólicos
US12208071B2 (en) * 2018-02-13 2025-01-28 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
JPH0738070B2 (ja) 1986-07-25 1995-04-26 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
EP0284240B2 (en) 1987-03-09 1993-06-16 EASTMAN KODAK COMPANY (a New Jersey corporation) Photographic silver halide materials and process comprising a pyrazolotriazole coupler
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU651835B2 (en) 1990-06-13 1994-08-04 Arnold Glazier Phosphorous prodrugs
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
EP0632048B1 (en) 1993-06-29 2001-03-21 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5780058A (en) 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
JPH09241284A (ja) 1996-03-08 1997-09-16 Koji Yamashita 新規なオキシアザホスホリン誘導体
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
JPH1197740A (ja) 1997-09-19 1999-04-09 Showa Denko Kk ＧａＰ発光ダイオード用エピタキシャルウェーハおよびＧａＰ発光ダイオード
ES2182379T3 (es) 1997-12-22 2003-03-01 Alza Corp Membrana de regulacion del regimen de liberacion para dispositivos de administracion controlada de farmacos.
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
WO1999033513A1 (en) 1997-12-31 1999-07-08 Alza Corporation Osmotic drug delivery monitoring system and method
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
CA2350246C (en) 1998-11-02 2010-04-27 Alza Corporation Controlled delivery of active agents
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
AU4537900A (en) 1999-05-17 2000-12-05 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
CA2374650A1 (en) 1999-05-24 2000-11-30 Penglie Zhang Inhibitors of factor xa
ATE329920T1 (de) 1999-09-10 2006-07-15 Novo Nordisk As Modulatoren der protein tyrosin phosphatase (ptpases)
DE10008329A1 (de) 2000-02-23 2001-08-30 Merck Patent Gmbh Aminosulfonylbiphenylderivate
CA2411552A1 (en) 2000-06-23 2002-01-03 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2002223501A1 (en) 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
JP2005511683A (ja) 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US20030212119A1 (en) 2001-12-20 2003-11-13 Jesper Lau Novel glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
EP1519723A1 (en) 2002-06-27 2005-04-06 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
CA2508581A1 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
US20040152750A1 (en) 2002-12-20 2004-08-05 Kodra Janos Tibor Novel glucagon antagonists
WO2004069158A2 (en) 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US7138529B2 (en) 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
EP1626717A4 (en) 2003-05-09 2009-09-09 Merck & Co Inc BENZIMIDAZOLE, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
JPWO2005054213A1 (ja) 2003-12-02 2007-12-06 塩野義製薬株式会社 ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
US20070015757A1 (en) 2003-12-19 2007-01-18 Novo Nordisk A/S Novel Glucagon Antagonists/Inverse Agonists
WO2005065680A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
ES2428538T3 (es) 2004-05-28 2013-11-08 Eli Lilly And Company Antagonistas del receptor de glucagón, preparación y usos terapéuticos
MXPA06014084A (es) 2004-06-04 2007-02-15 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y metodos de uso.
MXPA06014426A (es) 2004-06-14 2007-03-01 Lilly Co Eli Antagonistas del receptor de glucagon, preparacion y usos therapeuticos.
EP1768954A4 (en) 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
ES2332470T3 (es) 2005-02-11 2010-02-05 Eli Lilly And Company Derivados de tiofeno sustituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos.
CN101146762A (zh) 2005-03-21 2008-03-19 默克公司 取代的芳基和杂芳基衍生物
CA2600833A1 (en) 2005-03-30 2006-10-05 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7709658B2 (en) 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
CA2629223C (en) 2005-11-17 2013-08-06 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
AU2006340002B2 (en) 2005-11-17 2011-12-22 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
CA2629321C (en) 2005-11-18 2013-08-06 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
EP1957068B1 (en) 2005-11-22 2014-08-13 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
US7807702B2 (en) 2005-11-23 2010-10-05 Eli Lilly And Company Substituted thiophene carboxylic amide glucagon receptor antagonists, preparation and therapeutic uses
JP2009530381A (ja) 2006-03-23 2009-08-27 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、この化合物を含む組成物及び使用方法
WO2007136577A2 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2008001883A1 (en) 2006-06-29 2008-01-03 Nissan Chemical Industries, Ltd. α-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN102584685A (zh) 2006-12-02 2012-07-18 财团法人首尔大学校产学协力财团 作为ppar配体的芳基化合物及其用途
DK2129654T3 (da) 2007-02-09 2014-08-25 Metabasis Therapeutics Inc Antagonister af glucagonreceptoren
ES2615481T3 (es) 2008-08-13 2017-06-07 Metabasis Therapeutics, Inc. Antagonistas de glucagón
EP2734207A4 (en) * 2011-07-18 2015-06-17 Tokai Pharmaceuticals Inc NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
JP2017051900A (ja) 2015-09-08 2017-03-16 国立大学法人横浜国立大学 触媒とその製造方法
CN205117265U (zh) 2015-11-19 2016-03-30 北京美高科技发展有限公司 电缆式电液控制割管工具

Similar Documents

Publication Publication Date Title
JP2017519000A5 (enExample)
JP5275975B2 (ja) 高脂血症の予防及び／又は治療剤
JP6238460B2 (ja) 脂質異常症治療剤
JP2016500063A5 (enExample)
JP2009530398A5 (enExample)
CA2566945A1 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
EA020849B1 (ru) Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
JP2009522292A5 (enExample)
JP2007523155A5 (enExample)
JP2009537559A5 (enExample)
JP2014505017A5 (enExample)
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
RU2008123000A (ru) Соединения для лечения метаболических нарушений
JP2020100627A (ja) １５−ｈｅｐｅを含む組成物及びそれを使用する方法
CN1159305C (zh) 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
JP2020520949A5 (enExample)
RU2013127611A (ru) Модуляторы глюкагонового рецептора
JP2017515899A5 (enExample)
JP2018510206A5 (enExample)
US20200246314A1 (en) Dyslipidemia therapeutic agent
JP2019501971A5 (enExample)
Desai et al. Design and synthesis of potent and subtype-selective PPARα agonists
TW201618776A (zh) 脂質異常症治療劑
JP2018197273A (ja) 脂質異常症治療剤
JP2008081427A (ja) 分泌障害性疾患の予防及び／又は治療のための医薬